GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.


Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.


Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.


Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.


Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.


Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

Direct download: GRACEcast-258_Lung-Video_ASCO_2014_Immunotherapy_Since_2013.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.


Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Eroltinib for early-stage lung cancer.


Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.